Eli Lilly 2012 Annual Report Download - page 111

7
Alfred G. Gilman, M.D., Ph.D., Age 71, Director since
1995
Regental Professor of Pharmacology Emeritus,
University of Texas Southwestern Medical Center at
Dallas
Dr. Gilman is the regental professor of pharmacology
emeritus at the University of Texas Southwestern
Medical Center at Dallas. Dr. Gilman was on the faculty
of the University of Virginia School of Medicine from
1971 to 1981 and was named a professor of
pharmacology there in 1977. He previously served as
executive vice president for academic affairs and provost
of the University of Texas Southwestern Medical Center
at Dallas, dean of the University of Texas Southwestern
Medical School, and professor of pharmacology at the
University of Texas Southwestern Medical Center. He
held the Raymond and Ellen Willie Distinguished Chair
of Molecular Neuropharmacology, the Nadine and Tom
Craddick Distinguished Chair in Medical Science, and
the Atticus James Gill, M.D., Chair in Medical Science at
the university and was named a regental professor in
1995. Between 2009 and 2012, Dr. Gilman was the chief
scientific officer of the Cancer Prevention and Research
Institute of Texas. He is a director of Regeneron
Pharmaceuticals, Inc. Dr. Gilman was a recipient of the
Nobel Prize in Physiology or Medicine in 1994.
Qualifications: Dr. Gilman is a Nobel Prize-winning
pharmacologist, researcher, and professor. He has deep
expertise in basic science, including mechanisms of
drug action, and experience with pharmaceutical
discovery research. As the former dean of a major
medical school, he brings to the board important
perspectives of both the academic and practicing
medical communities.
Board committees: public policy and compliance;
science and technology (chair)
Karen N. Horn, Ph.D., Age 69, Director since 1987
Retired President, Private Client Services; Managing
Director, Marsh, Inc.
Ms. Horn served as president of private client services
and managing director of Marsh, Inc., a global provider
of risk and insurance services, from 1999 until her
retirement in 2003. Prior to joining Marsh, she was
senior managing director and head of international
private banking at Bankers Trust Company, chairman
and chief executive officer of Bank One, Cleveland, N.A.,
president of the Federal Reserve Bank of Cleveland,
treasurer of Bell Telephone Company of Pennsylvania,
and vice president of First National Bank of Boston.
Ms. Horn serves as director of T. Rowe Price Mutual
Funds, Simon Property Group, Inc., and Norfolk
Southern Corporation. She previously served on the
boards of Fannie Mae and Georgia-Pacific Corporation.
Ms. Horn has been senior managing director of Brock
Capital Group, a provider of financial advising and
consulting services, since 2004.
Qualifications: Ms. Horn is a former CEO with extensive
experience in various segments of the financial industry,
including banking and financial services. Through her
for-profit and her public-private partnership work, she
has significant experience in international economics
and finance. Ms. Horn has extensive corporate
governance experience through service on other public
company boards in a variety of industries.
Board committees: compensation (chair); directors and
corporate governance
William G. Kaelin, Jr., M.D., Age 55, Director since 2012
Professor, Department of Medicine and Associate
Director, Basic Science; Dana-Farber/Harvard Cancer
Center
Dr. Kaelin, who is currently serving under interim
election, joined the board in June 2012 and was referred
to the directors and corporate governance committee by
an incumbent independent director. Dr. Kaelin is a
professor in the Department of Medicine at the
Dana-Farber Cancer Institute and at the Brigham and
Women's Hospital, Harvard Medical School, where he
began his career as an independent investigator in 1992.
He currently serves as associate director, Basic Science,
for the Dana-Farber/Harvard Cancer Center. Dr. Kaelin
is a prominent member of the medical research
community and has received broad recognition for his
work in oncology research, including the Canada
Gairdner International Award and the Lefoulon-
Delalande Prize from the Institute of France. Dr. Kaelin
is a member of the Institute of Medicine, the National
Academy of Sciences, and the Association of American
Physicians.
Qualifications: Dr. Kaelin is a prominent medical
researcher and academician. He has extensive
experience at Harvard Medical School, a major medical
institution, as well as special expertise in oncology—a
key component of Lilly's business. He also has deep
expertise in basic science, including mechanisms of
drug action, and experience with pharmaceutical
discovery research.
Board Committees: finance; science and technology
John C. Lechleiter, Ph.D., Age 59, Director since 2005
Chairman, President, and Chief Executive Officer
Dr. Lechleiter has served as president and chief
executive officer of Lilly since April 1, 2008. He became
the chairman of the board of directors on January 1,
2009. He began work at Lilly in 1979 as a senior organic
chemist in process research and development. Prior to
joining Lilly, Dr. Lechleiter attended Xavier University
(Cincinnati, Ohio), where he earned a bachelor of
science degree in chemistry in 1975, and Harvard
University, where he earned master's and doctoral
degrees in organic chemistry in 1980. Dr. Lechleiter has
received honorary doctorates from Marian University